Scarica l'app Stockscreener
21.90
0.90%
-0.20
Dopo l'orario di chiusura:
21.76
-0.14
-0.64%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$22.10
Aprire:
$22.2
Volume 24 ore:
12.99M
Relative Volume:
1.59
Capitalizzazione di mercato:
$15.23B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
3.8761
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+4.34%
1M Prestazione:
+7.93%
6M Prestazione:
+93.46%
1 anno Prestazione:
+84.97%
Intervallo 1D:
$21.60
$22.56
Intervallo di 1 settimana:
$20.14
$22.56
Portata 52W:
$8.73
$22.56
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Confronta ROIV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
21.90 | 15.37B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant Sciences (ROIV): Ramaswamy Vivek sells $67.9 million in shares - Investing.com
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402Has The Bull Case Changed? - Yahoo! Finance Canada
Roivant Sciences (NASDAQ:ROIV) Given New $33.00 Price Target at The Goldman Sachs Group - MarketBeat
Roivant Sciences stock hits all-time high at 22.45 USD - Investing.com
Roivant Sciences price target raised to $32 from $29 at Leerink Partners By Investing.com - Investing.com South Africa
Roivant Sciences price target raised to $32 from $29 at Leerink Partners - Investing.com India
Roivant Sciences stock price target raised to $26 from $23 at H.C. Wainwright - Investing.com India
Immunovant (IMVT) Is Up 14.0% After $550 Million Follow-On Backed By Roivant SciencesWhat's Changed - simplywall.st
Headlands Technologies LLC Increases Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
BlackBarn Capital Partners LP Sells 125,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock holds Buy rating at Guggenheim after timeline updates By Investing.com - Investing.com South Africa
Massive Stock Acquisition: Roivant Sciences Bets Big on Immunovant - TipRanks
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares - MarketBeat
Roivant Sciences Boosts Investor Confidence With Advancements and Financing Moves - StocksToTrade
HC Wainwright & Co. Maintains Roivant Sciences (ROIV) Buy Recommendation - Nasdaq
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m By Investing.com - Investing.com Canada
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com
Roivant Sciences Sees Strategic Consolidation with Key Drug Advancements - timothysykes.com
Roivant Sciences Eyes Strategic Growth: Key Analyst Updates and Development Plans - timothysykes.com
Roivant Sciences stock holds Buy rating at Guggenheim after timeline updates - Investing.com Australia
Roivant Sciences (ROIV) president Venker sells $4.17 million in shares By Investing.com - Investing.com Australia
Roivant Sciences (ROIV) president Venker sells $4.17 million in shares - Investing.com
Roivant Updates Investors On Mosliciguat Development Plans - Citeline News & Insights
Why Is Roivant Sciences Stock Gaining Thursday?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week HighHere's Why - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year HighHere's What Happened - MarketBeat
Price-Driven Insight from (ROIV) for Rule-Based Strategy - news.stocktradersdaily.com
Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts - ts2.tech
HighVista Strategies LLC Sells 54,058 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant accelerates timeline for key drug programs, plans multiple launches By Investing.com - Investing.com Australia
Roivant Sciences Ltd Highlights Pipeline Progress at 2025 Investor Day - TradingView — Track All Markets
Roivant highlights continued pipeline progress and outlook for company's next phase of growth at 2025 Investor Day - marketscreener.com
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day - marketscreener.com
Roivant (Nasdaq: ROIV) outlines 3+ launches as $550M Immunovant deal extends runway - Stock Titan
Immunovant announces $550 million stock offering and clinical program updates - Investing.com
Marshall Wace LLP Acquires 683,327 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Immunovant Announces Pricing of $550 Million Common Stock Financing - The Manila Times
Immunovant (Nasdaq: IMVT) raises $550M to support potential IMVT-1402 Graves’ launch - Stock Titan
Psivant Therapeutics, Inc. announced that it has received $47.5 million in funding from YK Bioventures, Samsara BioCapital LLC, Roivant Sciences Ltd., LSV Capital Management, LLC, Eurofarma Laboratórios S.A. and other investos - marketscreener.com
WINTON GROUP Ltd Has $2.35 Million Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Norges Bank Invests $6.95 Million in Roivant Sciences Ltd. $ROIV - MarketBeat
A Roivant spinout bets on AI-designed drugs for immune conditions - Yahoo Finance
iSAM Funds UK Ltd Grows Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock hits all-time high at $21.36 By Investing.com - Investing.com Canada
Roivant Sciences stock hits all-time high at $21.36 - Investing.com
Roivant Sciences Ltd. $ROIV is SB Investment Advisers UK Ltd.'s 3rd Largest Position - MarketBeat
88,495 Shares in Roivant Sciences Ltd. $ROIV Acquired by Franklin Resources Inc. - MarketBeat
Cash per share of Roivant Sciences Ltd. – MUN:87S - TradingView
Affinity Asset Advisors LLC Purchases 250,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Earnings Beat: Why Roivant Sciences Ltd stock could rally in 2025Quarterly Portfolio Report & High Return Trade Guides - moha.gov.vn
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):